Afinitor (everolimus 10 mg) represents a groundbreaking approach in targeted cancer therapy. This drug, acting as an mTOR inhibitor, disrupts cancer cell proliferation and growth. The study of its pharmacokinetics unveils how Afinitor is processed in the body.
Pharmacokinetics
Upon oral administration, everolimus shows rapid absorption. Peak plasma concentrations occur within 1-2 hours post-dose. The drug exhibits a half-life of approximately 30 hours, facilitating once-daily dosing. The bioavailability of everolimus varies, contingent on dietary intake, with fat-rich meals decreasing systemic exposure.
Everolimus binds extensively to blood proteins, enhancing its distribution across tissues. Metabolism occurs primarily in the liver via CYP3A4 enzymes, and everolimus is subject to significant first-pass effect. Renal excretion contributes minimally, with fecal elimination accounting for the bulk of drug clearance.
Other Uses for Afinitor
Beyond cancer, Afinitor extends its utility to tuberous sclerosis complex (TSC)-associated seizures. It reduces seizure frequency, providing relief for those afflicted with this genetic disorder. Everolimus 10 mg also treats renal angiomyolipoma in patients with TSC.
Afinitor benefits patients with pancreatic neuroendocrine tumors, showcasing its versatility in managing diverse malignancies. This drug proves efficacious in HER2-negative breast cancer postmenopausal women, in combination with exemestane.
Who Can and Cannot Take Afinitor
Afinitor suits adults with advanced hormone receptor-positive breast cancer, renal cell carcinoma, and TSC. However, contraindications exist. Patients with severe hepatic impairment should avoid everolimus 10 mg.
Individuals allergic to everolimus or any of its components must not consume Afinitor. Caution applies to those with a history of infection, as everolimus suppresses immune response.
Pregnancy and Breastfeeding
Everolimus 10 mg poses risks during pregnancy, potentially harming fetal development. Women of childbearing age should employ effective contraception while on Afinitor. The drug’s impact during breastfeeding remains uncertain.
Lactating women should abstain from Afinitor therapy, given the potential excretion of everolimus in breast milk. Alternative treatments should be considered for nursing mothers.
Adverse Effects
Common adverse effects of Afinitor include stomatitis, fatigue, and rash. Patients may experience appetite loss or gastrointestinal disturbances. Regular monitoring mitigates severe complications.
Serious side effects, such as pneumonitis and nephrotoxicity, require immediate medical intervention. Everolimus 10 mg also increases infection susceptibility due to immunosuppression.
Afinitor Over the Counter
Afinitor is not available over the counter. It requires a prescription due to its potent nature and potential side effects. Healthcare professionals must evaluate patient suitability before prescribing everolimus 10 mg.
Consultation with a specialist ensures safe and effective treatment. Over-the-counter availability is inappropriate for such a targeted therapeutic agent.
| Condition | Usage |
|---|---|
| Advanced Breast Cancer | Approved |
| TSC-Associated Seizures | Approved |
- Rapid absorption post-oral intake
- Extensive tissue distribution
- Hepatic metabolism predominates
- Potential for fetal harm during pregnancy
- Prescription required for safe use
Everolimus 10 mg showcases its value in oncology and neurology, yet warrants caution. Adherence to guidelines ensures patient safety and maximizes therapeutic outcomes.